Industry-Led Consortia
Industry-Led Consortia supports industry and academic researchers developing translational evidence for novel therapeutics to expand treatment options for familial and sporadic ALS.
Browse similar grants
Funder: Target ALS
Due Dates: January 18, 2027 (LOI) | February 22, 2027 (Full proposal invitations) | April 5, 2027 (Full proposal) | June 15, 2027 (Decisions) | July 30, 2027 (Funds released)
Funding Amounts: Up to $130,000 per laboratory annually, with a $400,000 annual consortium cap, for two years
Summary: Supports industry-led academic collaborations building translational evidence for novel therapeutics for familial and sporadic ALS.
Key Information: Consortia must include 3–4 laboratories and a biotech/pharma Principal Investigator serving as Project Leader.
Description
Target ALS funds collaborative research to identify, develop, and validate novel ALS therapeutics and build robust translational data packages. The program brings industry and academic researchers together, providing direct support to both industry partners and academic investigators. Its goal is to expand therapeutic options for familial and sporadic ALS beyond the genetic forms that have benefited from recent advances.
Projects must focus on novel ALS targets with strong biological rationale validated, at least partly, through human samples or datasets. Therapeutic approaches may address C9orf72-ALS or non-genetic ALS, including drugs with potential to treat both ALS and frontotemporal dementia. Drug repurposing, SOD1-targeting therapies, FUS-targeting therapies, and broad discovery-based screening are outside the program’s scope.
